The association between inhaled corticosteroid and pneumonia in COPD patients: The improvement of patients’ life quality with COPD in Taiwan (IMPACT) study

International Journal of COPD

Volumn 11, Issue 1, 2016, Pages 2775-2783

  Wang, Cheng Yi ^a   Lai, Chih Cheng ^b   Yang, Wei Chih ^c   Lin, Chia Chieh ^a   Chen, Likwang ^c   Wang, Hao Chien ^d   Yu, Chong Jen ^d  

^a FU JEN CATHOLIC UNIVERSITY   (Taiwan)

^b CHI MEI MEDICAL CENTER   (Taiwan)

^c NATIONAL HEALTH RESEARCH INSTITUTES   (Taiwan)

^d NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

Author keywords

Chronic obstructive pulmonary disease; Inhaled corticosteroid; Pneumonia

Indexed keywords

BUDESONIDE; BUDESONIDE PLUS FORMOTEROL; CORTICOSTEROID; FLUTICASONE; FLUTICASONE PROPIONATE PLUS SALMETEROL; BRONCHODILATING AGENT; FLUTICASONE PROPIONATE PLUS SALMETEROL XINAFOATE;

AGED; ARTICLE; CASE CONTROL STUDY; CHRONIC OBSTRUCTIVE LUNG DISEASE; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG EXPOSURE; DRUG SAFETY; DRUG USE; FEMALE; HUMAN; MAJOR CLINICAL STUDY; MALE; PNEUMONIA; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTOR; TAIWAN; CHEMICALLY INDUCED; COMPARATIVE STUDY; CROSS-SECTIONAL STUDY; DRUG EFFECTS; FACTUAL DATABASE; INHALATIONAL DRUG ADMINISTRATION; LUNG; MIDDLE AGED; ODDS RATIO; PATHOPHYSIOLOGY; PSYCHOLOGY; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; STATISTICAL MODEL; TIME FACTOR; TREATMENT OUTCOME; VERY ELDERLY;

ADMINISTRATION, INHALATION; ADRENAL CORTEX HORMONES; AGED; AGED, 80 AND OVER; BRONCHODILATOR AGENTS; BUDESONIDE, FORMOTEROL FUMARATE DRUG COMBINATION; CASE-CONTROL STUDIES; CROSS-SECTIONAL STUDIES; DATABASES, FACTUAL; FEMALE; FLUTICASONE PROPIONATE, SALMETEROL XINAFOATE DRUG COMBINATION; HUMANS; LOGISTIC MODELS; LUNG; MALE; MIDDLE AGED; ODDS RATIO; PNEUMONIA; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUALITY OF LIFE; RISK ASSESSMENT; RISK FACTORS; TAIWAN; TIME FACTORS; TREATMENT OUTCOME;

EID: 84995701489     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S116750     Document Type: Article

References (30)

1. Lopez-Campos JL, Tan W, Soriano JB. Global burden of COPD. Respirology. 2016;21(1):14–23.
2. Lopez AD, Mathers CD, Ezzati M, Jamison DT, Murray CJ. Global and regional burden of disease and risk factors, 2001: systematic analysis of population health data. Lancet. 2006;367(9524):1747–1757.
3. Mannino DM, Buist AS. Global burden of COPD: risk factors, prevalence, and future trends. Lancet. 2007;370(9589):765–773.
4. Beran D, Zar HJ, Perrin C, Menezes AM, Burney P; Forum of International Respiratory Societies working group collaboration. Burden of asthma and chronic obstructive pulmonary disease and access to essential medicines in low-income and middle-income countries. Lancet Respir Med. 2015;3(2):159–170.
5. Bhatt SP, Wells JM, Dransfield MT. Cardiovascular disease in COPD: a call for action. Lancet Respir Med. 2014;2(10):783–785.
6. Pauwels RA, Rabe KF. Burden and clinical features of chronic obstructive pulmonary disease (COPD). Lancet. 2004;364(9434):613–620.
7. Wedzicha JA, Singh R, Mackay AJ. Acute COPD exacerbations. Clin Chest Med. 2014;35(1):157–163.
8. Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet. 2007;370(9589):786–796.
9. Decramer ML, Chapman KR, Dahl R, et al; INVIGORATE investigators. Once-daily indacaterol versus tiotropium for patients with severe chronic obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med. 2013;1(7):524–533.
10. Uzun S, Djamin RS, Kluytmans JA, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. Lancet Respir Med. 2014;2(5):361–368.
11. Zheng JP, Wen FQ, Bai CX, et al; PANTHEON study group. Twice daily N-acetylcysteine 600 mg for exacerbations of chronic obstructive pulmonary disease (PANTHEON): a randomised, double-blind placebo-controlled trial. Lancet Respir Med. 2014;2(3):187–194.
12. Gartlehner G, Hansen RA, Carson SS, Lohr KN. Efficacy and safety of inhaled corticosteroids in patients with COPD: a systematic review and meta-analysis of health outcomes. Ann Fam Med. 2006;4(3):253–262.
13. Matera MG, Cardaci V, Cazzola M, Rogliani P. Safety of inhaled corticosteroids for treating chronic obstructive pulmonary disease. Expert Opin Drug Saf. 2015;14(4):533–541.
14. Cumming RG, Mitchell P, Leeder SR. Use of inhaled corticosteroids and the risk of cataracts. N Engl J Med. 1997;337(1):8–14.
15. Garbe E, LeLorier J, Boivin JF, Suissa S. Inhaled and nasal glucocorticoids and the risks of ocular hypertension or open-angle glaucoma. JAMA. 1997;277(9):722–727.
16. Hubbard RB, Smith CJ, Smeeth L, Harrison TW, Tattersfield AE. Inhaled corticosteroids and hip fracture: a population-based case-control study. Am J Respir Crit Care Med. 2002;166(12 Pt 1):1563–1536.
17. Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med. 2001;345(13):941–947.
18. van Boven JF, de Jong-van den Berg LT, Vegter S. Inhaled corticosteroids and the occurrence of oral candidiasis: a prescription sequence symmetry analysis. Drug Saf. 2013;36(4):231–236.
19. Cheng SL, Su KC, Wang HC, Perng DW, Yang PC. Chronic obstructive pulmonary disease treated with inhaled medium- or high-dose corticosteroids: a prospective and randomized study focusing on clinical efficacy and the risk of pneumonia. Drug Des Devel Ther. 2014;8:601–607.
20. Nannini LJ, Poole P, Milan SJ, Kesterton A. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2013;(8):Cd006826.
21. Suissa S, Coulombe J, Ernst P. Discontinuation of inhaled corticosteroids in COPD and the risk reduction of Pneumonia. Chest. 2015;148(5):1177–1183.
22. Suissa S, Patenaude V, Lapi F, Ernst P. Inhaled corticosteroids in COPD and the risk of serious pneumonia. Thorax. 2013;68(11):1029–1036.
23. Janson C, Larsson K, Lisspers KH, et al. Pneumonia and pneumonia related mortality in patients with COPD treated with fixed combinations of inhaled corticosteroid and long acting beta2 agonist: observational matched cohort study (PATHOS). BMJ. 2013;346:f3306.
24. Finney L, Berry M, Singanayagam A, Elkin SL, Johnston SL, Mallia P. Inhaled corticosteroids and pneumonia in chronic obstructive pulmonary disease. Lancet Respir Med. 2014;2(11):919–932.
25. Kew KM, Seniukovich A. Inhaled steroids and risk of pneumonia for chronic obstructive pulmonary disease. Cochrane Database Syst Rev. 2014;(3):Cd010115.
26. Brattsand R, Miller-Larsson A. The role of intracellular esterification in budesonide once-daily dosing and airway selectivity. Clin Ther. 2003;25(Suppl C):C28–C41.
27. Dalby C, Polanowski T, Larsson T, Borgstrom L, Edsbacker S, Harrison TW. The bioavailability and airway clearance of the steroid component of budesonide/formoterol and salmeterol/fluticasone after inhaled administration in patients with COPD and healthy subjects: a randomized controlled trial. Respir Res. 2009;10:104.
28. Ek A, Larsson K, Siljerud S, Palmberg L. Fluticasone and budesonide inhibit cytokine release in human lung epithelial cells and alveolar macrophages. Allergy. 1999;54(7):691–699.
29. Rennard SI, Tashkin DP, McElhattan J, et al. Efficacy and tolerability of budesonide/formoterol in one hydrofluoroalkane pressurized metered-dose inhaler in patients with chronic obstructive pulmonary disease: results from a 1-year randomized controlled clinical trial. Drugs. 2009;69(5):549–565.
30. Thorsson L, Edsbacker S, Kallen A, Lofdahl CG. Pharmacokinetics and systemic activity of fluticasone via Diskus and pMDI, and of budesonide via Turbuhaler. Br J Clin Pharmacol. 2001;52(5):529–538.